Carisma Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview

Carisma Therapeutics

03/11/2023 14:58

* Carisma Therapeutics Inc  CARM.OQ   CARM.O  is expected
to show
a fall in quarterly revenue when it reports  results 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 97.0% decrease in revenue to $1.2 million from $40 million a
year ago, according to the mean estimate from 3 analysts, based
on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Carisma
Therapeutics Inc
is for a loss of 57 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Carisma
Therapeutics Inc is $10​, above​ its last closing price
of $3.01. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.60       -0.60      -0.49     Beat    17.9
 Mar. 31 2023  -0.89       -0.89      -1.93     Missed  -116.9
 Dec. 31 2022  -2.20       -2.20      -0.80     Beat    63.6​
 Sep. 30 2022  -1.60       -1.60      2.00      Beat    225
 ​​Jun.        -2.60       -2.60      -3.20     Missed  -23.1
 30 2022                                                
 Mar. 31 2022  -1.97       -2.00      0.00      Beat    100​
 Dec. 31 2021  -1.65       -1.47      0.80      Beat    154.5
 Sep. 30 2021  -1.60       -1.40      7.20      Beat    614.3
 This summary was machine generated November 3 at 14:58 GMT.  All
figures in US dollars  unless otherwise stated